Document is current
Any future updates will be listed below
-
Authors
van der Burg, Stijn J. C.
Fiore, Marco
Rutkowski, Piotr
Albertsmeier, Markus
Bonvalot, Sylvie
Grignol, Valerie P.
Raut, Chandrajit P.
Cananzi, Ferdinando C. M.
Mullinax, John E.
Gyorki, David E.
Pennacchioli, Elisabetta
Ford, Samuel J.
Nessim, Carolyn
Cardona, Kenneth
Callegaro, Dario
Skoczylas, Jacek
Lindner, Lars H.
Gronchi, Alessandro
Van Houdt, Winan J. https://orcid.org/0000-0002-2303-3468
,
- License Information
-
More Information
Article History
Received: 10 January 2025
Accepted: 26 March 2025
First Online: 15 May 2025
Disclosure
: Ferdinando Cananzi received a speaking fee from Istituto Gentili in 2022. John Mullinax is the inventor of the Moffitt Cancer Center’s licensed intellectual property (IP) related to the proliferation and expansion of tumor-infiltrating lymphocytes (TILs) to Iovance Biotherapeutics. Dr. Mullinax has participated in sponsored research agreements with Iovance Biotherapeutics, Intellia Therapeutics, and SQZ Biotech, has received research support from NIH-NCI (K08CA252642), Ocala Royal Dames, and V Foundation, and has received ad hoc consulting fees from Merit Medical, Lyell Immunopharma, and Iovance Biotherapeutics. The remaining authors have no conflicts of interest.
